• Fresenius launched Fresenius Ventures, a corporate venture capital unit, to invest in healthcare innovators from early rounds through growth stage.
• Planned investment volume exceeds EUR 200 million over the next 5 years, targeting areas adjacent to its BioPharma, MedTech, care provision platforms.
• Strategy aims to secure earlier access to new technologies, business models, founders, backed by clinical, regulatory, operational support.
• Dr. Thomas Michael Thestrup will lead the unit, bringing corporate venture capital experience from Angelini Ventures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2370572_en) on July 23, 2026, and is solely responsible for the information contained therein.